Ready to Use Biosimilar Cell Lines
You do not want to wait until you have your desired biosimilar cell line in hands? UGA Biopharma promote a broad spectrum of Ready to Use Biosimilar Cell Lines including documentation which are ready to out-license to a collaboration partner. In addition UGA Biopharma can accelerate your way to success by providing an optimized bioprocess, downstream process and analytical data and methods.
Ready To Use Biosimilar Cell Lines read more
Adalimumab Biosimilar
Full package ready for sales now:
Research Cell Bank (RCB) including safety testing
Optimized fermentation process (USP)
Optimized downstream purification process (DSP) and analytics
Including proof of activity of the expressed protein
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Aflibercept Biosimilar
Aflibercept is a recombinant fusion protein with complex
post-translational modifications. Therefore deep understanding of biosimilar
development is required to develop a biosimilar like Aflibercept.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Anakinra Biosimilar
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Bevacizumab Biosimilar
Remarkable Bevacizumab clone stability for at least 10 weeks of cultivation.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Certolizumab Biosimilar
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Darbepoetin alfa Biosimilar
Biosimilary of Darbepoetin alfa expressing cell line could be improved. Please consider the isolectical focusing (IEF) gel of Darbepoetin alfa biosimilars and the originator.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Eculizumab Biosimilar
Very good biosimilarity achieved in a challenging Eculizumab development project (IgG2/4 hybrid antibody).
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Etanercept Biosimilar
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Ipilimumab Biosimilar
Typical
charge profil of ther reference medical product of Ipilimumab.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Laronidase Biosimilar
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Natalizumab Biosimilar
The
primary structure of a biosimilar has to be identical to the originator
molecule. The result of the peptide mapping of the Natalizumab biosimilar is
depicted here.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Nivolumab Biosimilar
A product
concentration over 3 g/L has been obtained during a Nivolumab consistency run
in stirred bioreactors.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Pembrolizumab Biosimilar
Pembrolizumab
(IgG4) biosimilar development project has been finalized in a very short time
line – according to the High Speed Workflow of UGA Biopharma!
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Pertuzumab Biosimilar
Outstanding productivity higher than 5 g/L reached during the pertuzumab development project!
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Dupilumab Biosimilar
An
outstanding product concentration higher than 7 g/L could be reached during the
Dupilumab development project! The first CHOice® Medium works very
well for Dupilumab clones.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Under Development
Alirocumab Biosimilar
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Imiglucerase Biosimilar
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Mepolizumab Biosimilar
This biosimilar project is under development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Omalizumab Biosimilar
A product
concentration of 3 g/L has been obtained during the Omalizumab biosimilar
development project.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Dulaglutide Biosimilar
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Elosulfase Biosimilar
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Erenumab Biosimilar
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Galsulfase Biosimilar
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Idursulfase Biosimilar
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Panitumumab Biosimilar
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Disclaimer
Most of the listed medical products (ready to use biosimilars, biosimilars under development or biosimilar cell lines) are subject of patents, patent applications and supplementary protection certificates. Therefore, UGA Biopharma GmbH does only provide the medical product in small amounts and solely for research and development performed in accordance with the research exemption and the market authorization privilege as defined in DIRECTIVE 98/44/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 July 1998 on the legal protection of biotechnological inventions and in DIRECTIVE 2004/27/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use (implemented into the German Patent Act in Section 11 No. 2 and 2b) in order to protect the rights of the patent holder(s) of the medical product. Otherwise, until the expiration of the patents and supplementary protection certificates related to the medical product Eculizumab, it is not allowed to produce, offer, put on the market or use the offered product which is subject of the intellectual property rights or to possess such a product for the purposes referred to within the territorial scope of the intellectual property rights. In case of contravention, a penalty for breach of contract from the person acting against the above mentioned regulations can be demanded.
Back to products and services
Contact
UGA Biopharma GmbHNeuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail: info@ugabiopharma.com
Phone: +49(0)3302 / 2024900